Details for Patent: 9,693,989

Which drugs does patent 9,693,989 protect, and when does it expire?

Patent 9,693,989 protects TUKYSA and is included in one NDA.

This patent has fifty-three patent family members in twenty-nine countries.

Summary for Patent: 9,693,989

Title:	N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
Abstract:	This invention provides compounds of Formula I ##STR00001## wherein B, G, A, E, R.sup.1, R.sup.2, R.sup.3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
Inventor(s):	Lyssikatos; Joseph P. (Piedmont, CA), Hicks; Julie Marie (Erie, CO), Marmsater; Fredrik P. (Boulder, CO), Zhao; Qian (Superior, CO)
Assignee:	Array Biopharma, Inc. (Boulder, CO)
Application Number:	14/034,361
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 9,693,989

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No			Y			TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-002	Apr 17, 2020		RX	Yes	Yes			Y			TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER

International Family Members for US Patent 9,693,989

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E446294
Austria	E507224
Australia	2006315383
Australia	2010202330